| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $960.7K | 0.00% | 251.50K | +100% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TARA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 29, 2026 | Shefferman JesseChief Executive Officer | Stock Gift at price 0.00 per share. | 30K | — |
| Jun 28, 2026 | Shefferman JesseChief Executive Officer | Conversion of Exercise of derivative security at price 1.91 per share. | 215.7K | $411.96K |
| Jun 28, 2026 | Shefferman JesseChief Executive Officer | Sale at price 4.09 per share. | 215.7K | $882.16K |
| Apr 7, 2026 | Zummo JacquelineOfficer | Sale at price 5.40 per share. | 1.1K | $6.12K |
| Mar 31, 2026 | Zummo JacquelineOfficer | Sale at price 5.26 per share. | 22.6K | $118.86K |
| Jan 15, 2026 | Fabbio PatrickChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 28K | — |
| Jan 15, 2026 | Shefferman JesseChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 87K | — |
| Jan 15, 2026 | Zummo JacquelineChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jan 15, 2026 | Conkling WilliamOfficer | Stock Award(Grant) at price 0.00 per share. | 26K | — |
| Jan 15, 2026 | Fry HannahOfficer | Stock Award(Grant) at price 0.00 per share. | 9.5K | — |
| Jan 15, 2026 | Nicacio Leonardo Viana M.D.Officer | Stock Award(Grant) at price 0.00 per share. | 26K | — |
| Jun 26, 2025 | Shefferman JesseChief Executive Officer | Stock Gift at price 0.00 per share. | 18.7K | — |
| Jun 23, 2025 | Shefferman JesseChief Executive Officer | Stock Gift at price 0.00 per share. | 300K | — |
| Jun 1, 2025 | Conkling WilliamOfficer | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| May 13, 2025 | Levy Richard SDirector | Purchase at price 3.19 per share. | 20K | $63.80K |
| May 13, 2025 | Levy Richard SDirector | Purchase at price 3.19 per share. | 20K | $63.80K |
| Apr 14, 2025 | Nicacio Leonardo Viana M.D.Officer | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Mar 25, 2025 | Zummo JacquelineOfficer | Sale at price 4.53 per share. | 21.2K | $96.14K |
| Jan 23, 2025 | Fabbio PatrickChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 23.5K | — |
| Jan 23, 2025 | Shefferman JesseChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 65K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 32.8 | -10.2 | -18.1 | 2.3 | -12.8 | -17.8 | 2.6 | -1.5 | -21.0 | -14.1 | −50.8% | ||
| 2025 | -6.8 | -24.0 | 13.9 | -17.8 | -13.1 | -0.3 | 2.3 | 0.6 | 39.4 | 19.1 | 42.5 | -27.8 | +0.9% |
| 2024 | 36.0 | 78.8 | -12.1 | -25.7 | -5.7 | -26.0 | 7.2 | -10.3 | -8.5 | 37.2 | 19.9 | 75.4 | +181.6% |
| 2023 | 21.8 | 8.1 | -11.3 | 1.0 | -11.7 | -14.3 | 8.4 | -15.8 | -23.4 | -25.4 | 16.5 | 29.3 | −30.0% |
| 2022 | -22.8 | -11.1 | 10.4 | -28.4 | -8.7 | -12.3 | 2.0 | 15.4 | -14.2 | 3.7 | 15.0 | -24.1 | −60.3% |
| 2021 | -25.7 | -4.3 | -8.5 | -28.9 | -15.3 | 2.7 | -18.6 | 5.8 | -17.5 | 0.0 | -0.4 | -2.0 | −72.1% |
| 2020 | 98.2 | -12.3 | -19.3 | 6.5 | 122.0 | -46.1 | -14.9 | -14.2 | -21.4 | 6.6 | 34.1 | 0.7 | +47.6% |
| 2019 | 18.9 | 7.8 | -82.7 | -18.5 | 2.4 | -1.0 | -11.1 | -13.5 | -18.8 | -3.8 | 20.0 | 36.7 | −81.9% |
| 2018 | 18.4 | 0.0 | 11.1 | -14.0 | 0.0 | 14.0 | -12.2 | 9.3 | -17.0 | -17.9 | 3.8 | 36.7 | +19.5% |
| 2017 | 2.6 | -5.1 | -5.4 | -17.1 | -17.2 | 27.1 | -11.5 | -3.7 | 53.8 | -10.0 | -2.8 | 8.6 | −0.0% |
| 2016 | -39.8 | -42.3 | 43.9 | 26.1 | -34.6 | 25.9 | -0.4 | 10.2 | 5.8 | 6.1 | 3.0 | -81.4 | −87.7% |
| 2015 | 1.0 | 3.0 | 7.6 | 3.7 | 40.1 | 5.7 | -3.2 | -18.0 | -1.8 | -1.5 | 16.4 | -2.7 | +49.1% |
| 2014 | 5.4 | -1.3 | +4.0% |
Buy / hold / sell counts
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.